scispace - formally typeset
B

Birgit Schittek

Researcher at University of Tübingen

Publications -  116
Citations -  8225

Birgit Schittek is an academic researcher from University of Tübingen. The author has contributed to research in topics: Melanoma & Staphylococcus aureus. The author has an hindex of 48, co-authored 108 publications receiving 7366 citations. Previous affiliations of Birgit Schittek include University of Cologne.

Papers
More filters
Journal ArticleDOI

Dermcidin: a novel human antibiotic peptide secreted by sweat glands.

TL;DR: In sweat, a proteolytically processed 47–amino acid peptide was generated that showed antimicrobial activity in response to a variety of pathogenic microorganisms, indicating that sweat plays a role in the regulation of human skin flora through the presence of an antimicrobial peptide.
Journal ArticleDOI

Human commensals producing a novel antibiotic impair pathogen colonization

TL;DR: It is shown that nasal Staphylococcus lugdunensis strains produce lugdunin, a novel thiazolidine-containing cyclic peptide antibiotic that prohibits colonization by S. aureus, and a rare example of a non-ribosomally synthesized bioactive compound from human-associated bacteria.
Journal ArticleDOI

Maintenance of B-cell memory by long-lived cells generated from proliferating precursors

TL;DR: It is shown that after an initial phase of extensive proliferation after primary immunization, memory cells can persist in the organism for extended periods of time in the absence of cell division.
Journal ArticleDOI

Cathelicidin anti-microbial peptide expression in sweat, an innate defense system for the skin.

TL;DR: Results indicate that cathelicidin is secreted in human sweat, has potent anti-microbial activity against both gram-positive and gram-negative bacteria, and can, after processing from the preproform, provide a barrier for protection against infection.
Journal ArticleDOI

Metastatic pathways and time courses in the orderly progression of cutaneous melanoma.

TL;DR: A large number of patients who develop clinical metastases following treatment of a primary cutaneous melanoma initial present with locoregional metastases and one‐third initially present with distant metastases.